Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118417 · ClinicalTrials.gov registry record · Phase 2
Therapies for Treatment-Resistant Panic Disorder Symptoms
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00118417: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00118417 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 46 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00118417, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.
Primary Outcome
This measure is the change in points between baseline and endpoint scores on the Panic Disorder Severity Scale (PDSS). The PDSS is a 7-item scale with each item rated from 0 (none) to 4 (extreme), for a total score range of 0 to 28 points, and an established interrater reliability of 0.87.
Interventions
- DRUG Sertraline
- DRUG Clonazepam
- BEHAVIORAL Cognitive behavioral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 1999-03 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
What the finished NCT00118417 record still lists
NCT00118417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Sertraline is the first listed.
NCT00118417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00118417 about?
NCT00118417 is a clinical study titled "Therapies for Treatment-Resistant Panic Disorder Symptoms". This study will determine the effectiveness of different treatments for panic disorder symptoms in individuals who still have symptoms after initial treatment with medication.
What is the current status of trial NCT00118417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 1999-03. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00118417?
The interventions under investigation include: Sertraline (DRUG), Clonazepam (DRUG), Cognitive behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00118417?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00118417's enrollment target sits among peer trials
46 1286th of 2000 higher than 705 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia